Bulun S E, Zeitoun K M, Takayama K, Sasano H
Departments of Obstetrics and Gynecology and Molecular Genetics, University of Illinois at Chicago, 820 S. Wood St. M/C 808, Illinois 60612, USA.
J Mol Endocrinol. 2000 Aug;25(1):35-42. doi: 10.1677/jme.0.0250035.
Conversion of C(19) steroids to estrogens is catalyzed by aromatase in human ovary, placenta and extraglandular tissues such as adipose tissue, skin and the brain. Aromatase activity is not detectable in normal endometrium. In contrast, aromatase is expressed aberrantly in endometriosis and is stimulated by prostaglandin E(2) (PGE(2)).( )This results in local production of estrogen, which induces PGE(2) formation and establishes a positive feedback cycle. Another abnormality in endometriosis, i.e. deficient hydroxysteroid dehydrogenase (17beta-HSD) type 2 expression, impairs the inactivation of estradiol to estrone. These molecular aberrations collectively favor accumulation of increasing quantities of estradiol and PGE(2 )in endometriosis. The clinical relevance of these findings was exemplified by the successful treatment of an unusually aggressive case of postmenopausal endometriosis using an aromatase inhibitor.
在人类卵巢、胎盘以及腺外组织(如脂肪组织、皮肤和大脑)中,芳香化酶可催化C(19)甾体转化为雌激素。正常子宫内膜中检测不到芳香化酶活性。相反,芳香化酶在子宫内膜异位症中异常表达,并受到前列腺素E(2)(PGE(2))的刺激。这导致雌激素在局部产生,进而诱导PGE(2)的形成,并建立一个正反馈循环。子宫内膜异位症的另一个异常情况,即2型羟类固醇脱氢酶(17β-HSD)表达不足,会损害雌二醇向雌酮的失活。这些分子异常共同促使子宫内膜异位症中雌二醇和PGE(2)的量不断积累。使用芳香化酶抑制剂成功治疗一例异常侵袭性绝经后子宫内膜异位症病例,例证了这些发现的临床意义。